Drug Profile
OS 2966
Alternative Names: OS-2966; OS2966tLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator OncoSynergy
- Class Antineoplastics; Antipsoriatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD29 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma
- Preclinical Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Traumatic brain injuries
- No development reported Solid tumours
- Discontinued Ebola virus infections
Most Recent Events
- 18 Mar 2024 OS 2966 is still in phase-I development in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion)
- 27 Feb 2023 OncoSynergy and Infuseon Therapeutics terminates a phase I trial in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoural) due to slow enrolment and financial constraints (NCT04608812)